Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy.
AuthorsHaller, J C
Brown, S B
Roberts, D J
AffiliationSchool of Medicine, Department of Colour Chemistry, Schools of Biomedical Sciences, and Biochemistry and Molecular Biology, University of Leeds, LS2 9JT, U.K.
MetadataShow full item record
AbstractBACKGROUND: Superficial basal cell carcinomas of the skin (sBCC) often respond poorly to single-treatment aminolaevulinic acid-based photodynamic therapy (ALA-PDT), with a number of reports indicating a relapse rate of 50% or more. OBJECTIVES: To determine whether a second treatment at seven days can improve the response. METHODS: Twenty-six lesions were treated twice with ALA-PDT, with an interval of 7 days between the two treatment sessions. RESULTS: We observed a complete response rate of 100% 1 month after treatment. Only one lesion relapsed (16 months post-PDT), a relapse rate of 4% (median follow up 27 months; range 15-45 months). Cosmetic results were excellent. CONCLUSIONS: We consider routine double treatments with ALA-PDT to be an effective approach to the management of sBCC, particularly those located in anatomically difficult, or cosmetically sensitive, sites.
CitationRoutine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. 2000, 143 (6):1270-5 Br. J. Dermatol.
JournalBritish Journal of Dermatology
- Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial.
- Authors: de Vijlder HC, Sterenborg HJ, Neumann HA, Robinson DJ, de Haas ER
- Issue date: 2012 Nov
- High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study.
- Authors: Christensen E, Mørk C, Skogvoll E
- Issue date: 2012 Jun
- Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial.
- Authors: Kessels JPHM, Kreukels H, Nelemans PJ, Roozeboom MH, van Pelt H, Mosterd K, de Haas ERM, Kelleners-Smeets NWJ
- Issue date: 2018 May
- A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy.
- Authors: Morton CA, Dominicus R, Radny P, Dirschka T, Hauschild A, Reinhold U, Aschoff R, Ulrich M, Keohane S, Ekanayake-Bohlig S, Ibbotson S, Ostendorf R, Berking C, Gröne D, Schulze HJ, Ockenfels HM, Jasnoch V, Kurzen H, Sebastian M, Stege H, Staubach P, Gupta G, Hübinger F, Ziabreva I, Schmitz B, Gertzmann A, Lübbert H, Szeimies RM
- Issue date: 2018 Aug
- Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
- Authors: Roozeboom MH, Nelemans PJ, Mosterd K, Steijlen PM, Arits AH, Kelleners-Smeets NW
- Issue date: 2015 Mar